NewsMV
A potential $400 billion combination between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) is meeting organized resistance from AstraZeneca's own shareholders before any definitive agreement has been filed.
Investors are pressing on two fault lines: a looming patent cliff at the British drugmaker and the antitrust risks embedded in a deal of this scale.
The next milestone to watch is any formal announcement of binding terms from either party. Shareholder concerns center on pipeline exposure and regulatory completion risk The objections are structural, not cosmetic.
On the first track, the patent cliff: AstraZeneca faces a known revenue exposure window as key drugs lose exclusivity, and shareholders are pressing on whether a merger with Bristol Myers Squibb resolves that problem or simply adds a new layer of execution risk on top of it.
Keep reading